185 related articles for article (PubMed ID: 28859739)
21. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial.
Reich K; Ortonne JP; Kerkmann U; Wang Y; Saurat JH; Papp K; Langley R; Griffiths CE
Dermatology; 2010; 221(2):172-8. PubMed ID: 20628238
[TBL] [Abstract][Full Text] [Related]
22. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
Wong IT; Shojania K; Dutz J; Tsao NW
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
[TBL] [Abstract][Full Text] [Related]
23. No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasis.
Strober BE; Langley RGB; Menter A; Magid M; Porter B; Fox T; Safi J; Papavassilis C
Br J Dermatol; 2018 Feb; 178(2):e105-e107. PubMed ID: 28991372
[No Abstract] [Full Text] [Related]
24. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials.
Lebwohl MG; Papp KA; Marangell LB; Koo J; Blauvelt A; Gooderham M; Wu JJ; Rastogi S; Harris S; Pillai R; Israel RJ
J Am Acad Dermatol; 2018 Jan; 78(1):81-89.e5. PubMed ID: 28985956
[TBL] [Abstract][Full Text] [Related]
25. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.
Bilal J; Berlinberg A; Bhattacharjee S; Trost J; Riaz IB; Kurtzman DJB
J Dermatolog Treat; 2018 Sep; 29(6):569-578. PubMed ID: 29532693
[TBL] [Abstract][Full Text] [Related]
26. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
Croxtall JD
Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
[TBL] [Abstract][Full Text] [Related]
27. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients.
Masson Regnault M; Konstantinou MP; Khemis A; Poulin Y; Bourcier M; Amelot F; Bulaï Livideanu C; Paul C
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1491-1496. PubMed ID: 28585707
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies.
Endres CJ; Salinger DH; Köck K; Gastonguay MR; Martin DA; Klekotka P; Nirula A; Gibbs MA
J Clin Pharmacol; 2014 Nov; 54(11):1230-8. PubMed ID: 24846347
[TBL] [Abstract][Full Text] [Related]
29. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
[TBL] [Abstract][Full Text] [Related]
30. Depression? It's the Disease NOT the Drug.
Kircik LH
J Drugs Dermatol; 2018 Aug; 17(8):s28. PubMed ID: 30124736
[TBL] [Abstract][Full Text] [Related]
31. A Closer Look at the Data Regarding Suicidal Ideation and Behavior in Psoriasis Patients: The Case of Brodalumab.
Rodriguez-Bolanos F; Gooderham M; Papp K
Skin Therapy Lett; 2019 Jul; 24(4):1-4. PubMed ID: 31339678
[TBL] [Abstract][Full Text] [Related]
32. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
[TBL] [Abstract][Full Text] [Related]
33. Tumor necrosis factor (TNF) inhibitors revolutionalized therapy for both psoriasis and psoriatic arthritis. Foreword.
Gottlieb AB
Am J Clin Dermatol; 2014 Feb; 15 Suppl 1():S3-4. PubMed ID: 24777570
[No Abstract] [Full Text] [Related]
34. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
Al-Salama ZT; Scott LJ
Am J Clin Dermatol; 2018 Dec; 19(6):907-918. PubMed ID: 30467781
[TBL] [Abstract][Full Text] [Related]
35. Anti-interleukin-17 treatment of psoriasis.
Jinna S; Strober B
J Dermatolog Treat; 2016 Aug; 27(4):311-5. PubMed ID: 26943806
[TBL] [Abstract][Full Text] [Related]
36. Secukinumab for plaque psoriasis.
Ordenes-Cavieres G; Andino-Navarrete R
Medwave; 2018 Nov; 18(7):e7364. PubMed ID: 30507896
[TBL] [Abstract][Full Text] [Related]
37. The impact of long-term secukinumab treatment on Epstein-Barr virus and cytomegalovirus loads in patients with psoriasis.
Chiu HY; Chan CC; Tsai TF
Int J Dermatol; 2016 Nov; 55(11):e600-e602. PubMed ID: 27261186
[No Abstract] [Full Text] [Related]
38. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
Papp KA; Reich K; Paul C; Blauvelt A; Baran W; Bolduc C; Toth D; Langley RG; Cather J; Gottlieb AB; Thaçi D; Krueger JG; Russell CB; Milmont CE; Li J; Klekotka PA; Kricorian G; Nirula A
Br J Dermatol; 2016 Aug; 175(2):273-86. PubMed ID: 26914406
[TBL] [Abstract][Full Text] [Related]
39. Brodalumab: A Review in Moderate to Severe Plaque Psoriasis.
Blair HA
Drugs; 2018 Mar; 78(4):495-504. PubMed ID: 29516365
[TBL] [Abstract][Full Text] [Related]
40. Extensive plaque psoriasis successfully treated with adalimumab (Humira).
Sladden MJ; Mortimer NJ; Hutchinson PE
Br J Dermatol; 2005 May; 152(5):1091-2. PubMed ID: 15888191
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
